Business Context and Reporting Period
Company: Biorestorative Therapies, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 4, 2019 (Earliest event reported)
Reporting Period: Events occurring between December 31, 2018, and January 9, 2019.
Key Financial Metrics and Transactions
This filing details specific debt financing and debt-for-equity exchange transactions rather than standard periodic financial performance metrics (revenue, profit, cash flow).
- New Debt Issuance: Issued promissory notes with an aggregate principal amount of $675,000 to accredited investors.
- Debt Terms: Interest rate of 15% per annum; maturity of six months from issuance.
- Conversion Features: Notes are convertible at $0.60 per share. Includes a five-year warrant to purchase shares equal to the conversion amount at an exercise price of $0.80 per share.
- Debt-for-Equity Exchange: Issued 801,280 shares of common stock to settle outstanding indebtedness totaling $264,548 (inclusive of accrued interest).
Material Changes
The filing reports material changes in the company's capital structure through the following actions:
- Creation of a direct financial obligation of $675,000 via new convertible promissory notes.
- Reduction of outstanding indebtedness by $264,548 through the issuance of unregistered equity securities.
- Issuance of unregistered equity securities (801,280 shares) pursuant to Section 4(a)(2) and Section 3(a)(9) of the Securities Act of 1933.
Outlook, Risks, and Management Commentary
Management Commentary: The filing contains no forward-looking guidance, outlook, or qualitative management commentary regarding future operations or strategy. The text is limited to the factual description of the financing transactions.
Risks and Contingencies: The filing does not explicitly list new risk factors. However, the issuance of convertible debt with a 15% interest rate and warrants implies potential future dilution of existing shareholders upon conversion or warrant exercise.
Unusual Items: The filing does not disclose any unusual items, restatements, or legal contingencies beyond the standard debt financing activities.
Investor Verification Checklist
- Verify the total outstanding debt load post-transaction to assess liquidity pressure given the 15% interest rate and six-month maturity.
- Confirm the exact number of shares outstanding after the issuance of 801,280 shares for debt settlement and potential future dilution from the $675,000 in convertible notes.
- Review the full text of Exhibit 10.1 (Form of Convertible Promissory Note) for specific adjustment mechanisms regarding the conversion price ($0.60) and warrant exercise price ($0.80).
- Check subsequent filings to determine if the company has sufficient cash flow to service the new debt or if further equity dilution is imminent.